United Kingdom

JCVI publishes COVID-19 vaccine advisory for fall promotion program

Joint Committee on Vaccination and Immunization (JCVI:) published its advice on which vaccines should be used in this year’s fall booster program.

All available boosters provide good protection against severe disease from COVID-19, and the Committee emphasized that receiving a timely booster before the winter season is more important for those eligible than the type of vaccine received.

Vaccines recommended for use in the fall booster program are:

For adults 18 years and older.

  • Moderna mRNA (Spikevax) Bivalent Omicron BA.1/Original Wild-Type Vaccine
  • Moderna mRNA (Spikevax) The original “wild-type” vaccine
  • Pfizer-BioNTech mRNA (Comirnaty) Original “wild-type” vaccine
  • In exceptional circumstances, Novavax Matrix-M adjuvanted wild-type vaccine (Nuvaxovid) may be used when no clinically relevant alternative UK-approved COVID-19 vaccine is available.

For people aged 12 to 17.

  • Pfizer-BioNTech mRNA (Comirnaty) Original “wild-type” vaccine

For people from 5 to 11 years old.

  • Pfizer-BioNTech mRNA (Comirnaty) Original Formulation of Pediatric “Wild-Type” Vaccine

“Bivalent” vaccines have been developed by manufacturers worldwide since the emergence and dominance of the Omicron variant. These vaccines contain two different antigens (substances that trigger an immune response) based on two different COVID-19 strains or variants. Original mRNA vaccines contain a single antigen (monovalent) based on the original “wild-type” strain.

Studies have shown that the Moderna bivalent vaccine elicits a marginally higher immune response to some variants than the Moderna mRNA Original “wild-type” vaccine. The clinical significance of these small differences is uncertain.

The committee will consider further bivalent vaccines for use in the program as they are approved by the organization MHRA:.

In his final advice JCVI: stated that it would be preferable if possible to offer one type of booster vaccine throughout the fall program for simplicity of deployment.

Professor Wei Shen Lim, Head of the Department of Vaccines against COVID-19 JCVI:said:

All available booster vaccines offer very good protection against severe disease from COVID-19. As more vaccines continue to be developed and approved, JCVI: will discuss the benefits of including them in the UK programme.

It is important that everyone who is eligible get a booster this fall, regardless of which vaccine is offered. This will increase your protection against becoming seriously ill from COVID-19 as we move into winter.

Dr. Mary Ramsay, Head of Immunization UKHSA:said:

Although cases of COVID-19 are currently relatively low, we expect the virus to spread more widely during the winter months.

A booster is recommended for those at higher risk of severe illness, and by getting a booster this fall, you’ll boost your protection before the winter months, when respiratory viruses are usually at their peak.

NHS England will confirm details of how and when eligible people can access the autumn booster in due course.

JCVI publishes COVID-19 vaccine advisory for fall promotion program

SourceJCVI publishes COVID-19 vaccine advisory for fall promotion program

Back to top button